LiveTata-Backed Fitness Chain Cult.fit Ready to Launch Its IPO in 12-18 Months
Tata-backed fitness chain Cult.fit plans to launch its IPO in the next 12-18 months, executives at the company told Moneycontrol, although they could not disclose...
Category : Latest News
NSE Floats Consultation on Index Rules Amid HDFC-HDFC bank merger
NSE Indices Ltd, a subsidiary of the National Stock Exchange, plans to change the policy of merger and demerger of index constituents for equity indices...
Vodafone Idea Considers Raising Debt Via Convertible Bonds
Telecom operator Vodafone Idea‘s board will consider and evaluate a proposal to issue convertible bonds to the supplier on October 21, the company said in...
Tata Motors Wins Order for 200 Electronic Buses to be Operated in J&K
On 18 October 2022, Tata Motors announced that it won the tender of 200 electric buses floated by Jammu Smart City for Jammu and Srinagar....
Piramal Pharma Shares Hit 5% Low Circuit After Its Listing
The Shares of Piramal Pharma entity plunged 5% to hit its lower circuit at Rs 191.75 per share after inaugural at Rs 201.8 on the...
Asia’s Richest Banker, Uday Kotak Weighs $1 Billion Real Estate Fund
According to people familiar with the matter, Kotak Investment Advisors Limited, supported by Asia’s richest banker Uday Kotak, is considering raising about $1 billion for...
Netflix Reverses Subscriber Decline, Shares Soar 14%
Netflix Inc reversed customer losses that have hit its stock this year and expects more growth, reassuring Wall Street as it prepares to offer new...
Arihant Capital Markets Ltd Spikes 4.01%
Arihant Capital Markets Ltd has lost 8.6 per cent over September as compared to a 1.71 per cent fall in the S&P BSE Financial Services...
Most Asian Stocks Extend Gains as Markets Await UK Inflation Data
Asian shares were mostly up on Wednesday as US corporate earnings boosted sentiment, while traders awaited UK inflation data later in the day to see...
J&J Looks at Job Cuts Despite Better Q3 Earnings
On Tuesday, Johnson & Johnson posted better-than-expected Q3 earnings on strong demand for its cancer drug Darzalex. However, the company said it may still cut...